PL3752516T3 - Dinukleotydy cykliczne jako środki przeciwnowotworowe - Google Patents
Dinukleotydy cykliczne jako środki przeciwnowotworoweInfo
- Publication number
- PL3752516T3 PL3752516T3 PL19707595T PL19707595T PL3752516T3 PL 3752516 T3 PL3752516 T3 PL 3752516T3 PL 19707595 T PL19707595 T PL 19707595T PL 19707595 T PL19707595 T PL 19707595T PL 3752516 T3 PL3752516 T3 PL 3752516T3
- Authority
- PL
- Poland
- Prior art keywords
- anticancer agents
- cyclic dinucleotides
- dinucleotides
- cyclic
- anticancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862629956P | 2018-02-13 | 2018-02-13 | |
US16/272,172 US10519187B2 (en) | 2018-02-13 | 2019-02-11 | Cyclic dinucleotides as anticancer agents |
EP19707595.5A EP3752516B1 (en) | 2018-02-13 | 2019-02-13 | Cyclic dinucleotides as anticancer agents |
PCT/US2019/017740 WO2019160884A1 (en) | 2018-02-13 | 2019-02-13 | Cyclic dinucleotides as anticancer agents |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3752516T3 true PL3752516T3 (pl) | 2022-05-02 |
Family
ID=67542132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL19707595T PL3752516T3 (pl) | 2018-02-13 | 2019-02-13 | Dinukleotydy cykliczne jako środki przeciwnowotworowe |
Country Status (17)
Country | Link |
---|---|
US (2) | US10519187B2 (pl) |
EP (1) | EP3752516B1 (pl) |
JP (1) | JP7296405B2 (pl) |
KR (1) | KR20200120683A (pl) |
CN (1) | CN111902420B (pl) |
AR (1) | AR114369A1 (pl) |
DK (1) | DK3752516T3 (pl) |
ES (1) | ES2909616T3 (pl) |
HR (1) | HRP20220520T1 (pl) |
HU (1) | HUE058662T2 (pl) |
LT (1) | LT3752516T (pl) |
PL (1) | PL3752516T3 (pl) |
PT (1) | PT3752516T (pl) |
RS (1) | RS63128B1 (pl) |
SI (1) | SI3752516T1 (pl) |
TW (1) | TW202003539A (pl) |
WO (1) | WO2019160884A1 (pl) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
CA3084569A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
US11161864B2 (en) | 2018-10-29 | 2021-11-02 | Venenum Biodesign, LLC | Sting agonists |
US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
WO2021146391A1 (en) * | 2020-01-16 | 2021-07-22 | Bristol-Myers Squibb Company | Reagents and their use for modular enantiodivergent synthesis of c–p bonds |
EP4134098A4 (en) | 2020-04-10 | 2024-05-15 | ONO Pharmaceutical Co., Ltd. | CANCER THERAPY METHODS |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
DK2559690T3 (en) | 2005-05-10 | 2016-04-25 | Incyte Holdings Corp | Modulators of indoleamine 2,3-dioxygenase and methods of use thereof |
TWI382974B (zh) | 2005-12-20 | 2013-01-21 | Incyte Corp | 作為吲哚胺2,3-二氧化酶調節劑之n-羥基甲脒基雜環化物 |
JP5319532B2 (ja) | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | インドールアミン2,3−ジオキシゲナーゼのモジュレーターとしてのn−ヒドロキシアミジノヘテロサイクル |
CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
EP3124046B1 (en) | 2007-07-12 | 2019-12-25 | GITR, Inc. | Combination therapies employing gitr binding molecules |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
CA2707308C (en) | 2007-11-30 | 2016-08-02 | Newlink Genetics Corporation | Ido inhibitors |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
IN2015DN02826A (pl) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
MA34780B1 (fr) | 2009-12-10 | 2014-01-02 | Hoffmann La Roche | Anticorps se liant de façon préférentielle au domaine extracellulaire 4 de csf1r human et leur utilisation |
GEP20166442B (en) | 2010-03-04 | 2016-03-10 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
RU2617966C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
MX2012010014A (es) | 2010-03-05 | 2012-09-21 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
PT2566517T (pt) | 2010-05-04 | 2019-01-24 | Five Prime Therapeutics Inc | Anticorpos que ligam csf1r |
NZ714128A (en) | 2010-09-09 | 2017-10-27 | Pfizer | 4-1bb binding molecules |
NO2694640T3 (pl) | 2011-04-15 | 2018-03-17 | ||
RS57324B1 (sr) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antitela i drugi molekuli koji vezuju b7-h1 i pd-1 |
CA2853889A1 (en) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
EP2812355A4 (en) | 2012-02-06 | 2016-03-02 | Hoffmann La Roche | COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
EP3539984A1 (en) | 2012-05-11 | 2019-09-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
EP2854843A4 (en) | 2012-05-31 | 2016-06-01 | Sorrento Therapeutics Inc | ANTIGEN BINDING PROTEINS THAT BIND PD-L1 |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
AU2013308635A1 (en) | 2012-08-31 | 2015-03-12 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
LT2992017T (lt) | 2013-05-02 | 2021-02-25 | Anaptysbio, Inc. | Antikūnai nukreipti prieš programuotos žūties baltymą-1 (pd-1) |
CA2913977C (en) | 2013-05-31 | 2022-11-29 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
WO2015035606A1 (en) | 2013-09-13 | 2015-03-19 | Beigene, Ltd. | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
PL3081576T3 (pl) | 2013-12-12 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
ES2692226T3 (es) | 2014-06-04 | 2018-11-30 | Glaxosmithkline Intellectual Property Development Limited | Dinucleótidos cíclicos como moduladores de STING |
CA2978942A1 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
BR112018002757A8 (pt) | 2015-08-13 | 2023-04-11 | Merck Sharp & Dohme | Composto, composição farmacêutica, e, métodos para induzir uma resposta imune, para induzir uma produção de interferon tipo i e para tratamento de um distúrbio |
EP3402801A1 (en) | 2016-01-11 | 2018-11-21 | Innate Tumor Immunity, Inc. | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
WO2018138685A2 (en) | 2017-01-27 | 2018-08-02 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
WO2019023459A1 (en) | 2017-07-28 | 2019-01-31 | Bristol-Myers Squibb Company | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
EP3676279B1 (en) | 2017-08-31 | 2021-12-01 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
JP7316263B2 (ja) | 2017-08-31 | 2023-07-27 | ブリストル-マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
BR112020009126A2 (pt) | 2017-11-10 | 2020-10-20 | Takeda Pharmaceutical Company Limited | compostos do modulador sting e métodos de fabricação e uso |
-
2019
- 2019-02-11 US US16/272,172 patent/US10519187B2/en active Active
- 2019-02-13 WO PCT/US2019/017740 patent/WO2019160884A1/en unknown
- 2019-02-13 PT PT197075955T patent/PT3752516T/pt unknown
- 2019-02-13 HU HUE19707595A patent/HUE058662T2/hu unknown
- 2019-02-13 KR KR1020207026044A patent/KR20200120683A/ko not_active Application Discontinuation
- 2019-02-13 ES ES19707595T patent/ES2909616T3/es active Active
- 2019-02-13 SI SI201930199T patent/SI3752516T1/sl unknown
- 2019-02-13 EP EP19707595.5A patent/EP3752516B1/en active Active
- 2019-02-13 CN CN201980012869.9A patent/CN111902420B/zh active Active
- 2019-02-13 RS RS20220372A patent/RS63128B1/sr unknown
- 2019-02-13 HR HRP20220520TT patent/HRP20220520T1/hr unknown
- 2019-02-13 JP JP2020564814A patent/JP7296405B2/ja active Active
- 2019-02-13 LT LTEPPCT/US2019/017740T patent/LT3752516T/lt unknown
- 2019-02-13 TW TW108104810A patent/TW202003539A/zh unknown
- 2019-02-13 AR ARP190100352A patent/AR114369A1/es unknown
- 2019-02-13 DK DK19707595.5T patent/DK3752516T3/da active
- 2019-02-13 PL PL19707595T patent/PL3752516T3/pl unknown
- 2019-11-14 US US16/683,667 patent/US11339185B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11339185B2 (en) | 2022-05-24 |
HUE058662T2 (hu) | 2022-09-28 |
ES2909616T3 (es) | 2022-05-09 |
KR20200120683A (ko) | 2020-10-21 |
CN111902420A (zh) | 2020-11-06 |
TW202003539A (zh) | 2020-01-16 |
US20200079815A1 (en) | 2020-03-12 |
AR114369A1 (es) | 2020-08-26 |
JP7296405B2 (ja) | 2023-06-22 |
SI3752516T1 (sl) | 2022-05-31 |
DK3752516T3 (da) | 2022-04-11 |
US20190248828A1 (en) | 2019-08-15 |
JP2021513562A (ja) | 2021-05-27 |
CN111902420B (zh) | 2024-02-02 |
EP3752516B1 (en) | 2022-02-23 |
RS63128B1 (sr) | 2022-05-31 |
LT3752516T (lt) | 2022-05-10 |
EP3752516A1 (en) | 2020-12-23 |
PT3752516T (pt) | 2022-03-31 |
HRP20220520T1 (hr) | 2022-05-27 |
WO2019160884A1 (en) | 2019-08-22 |
US10519187B2 (en) | 2019-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3665237T3 (en) | Compositions | |
LT3752516T (lt) | Cikliniai dinukleotidai kaip priešvėžiniai agentai | |
ZA201704732B (en) | Cyclic dinucleotides useful for the treatment of inter alia cancer | |
ZA202002898B (en) | Anticancer agents | |
ZAA201800984S (en) | Motors | |
ZA202004317B (en) | Immunostimulatory compositions | |
GB201719480D0 (en) | Compositions | |
IL259575B (en) | Preparations that stimulate the immune system | |
GB201707909D0 (en) | Compositions | |
GB2562241B (en) | Vaccine compositions | |
GB201707454D0 (en) | Compositions | |
PL3609464T3 (pl) | Kompozycje na bazie ksantohumolu | |
IL271603A (en) | Immunogenic preparations | |
IL290244A (en) | Anti-cancer substances | |
SG11202104832VA (en) | Anticancer composition | |
HK1253336A1 (zh) | 吲哚並吡咯啉抗腫瘤藥物 | |
GB201718251D0 (en) | Vaccine Compositions | |
GB201717712D0 (en) | Compositions | |
GB201817903D0 (en) | Anticancer treatment | |
DK3579865T3 (en) | Therapeutic compositions | |
GB2564901B (en) | Vaccine compositions | |
GB201718145D0 (en) | Rotor | |
GB201713811D0 (en) | Therapeutic compositions | |
GB201713226D0 (en) | Compositions | |
GB201710068D0 (en) | Compositions |